Vise Technologies’s Haemonetics HAE Stock Holding History

Vise Technologies’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$221K	Buy	2,825 +225	+9%	+$18.1K	0.02%	728
2024 Q3	$209K	Sell	2,600 -973	-27%	-$78.6K	0.03%	556
2024 Q2	$296K	Buy	+3,573	New	+$314K	0.05%	315
2023 Q4	–	Sell	-5,367	Closed	-$481K	–	359
2023 Q3	$481K	Sell	5,367 -2,871	-35%	-$256K	0.12%	175
2023 Q2	$701K	Buy	8,238 +3,020	+58%	+$255K	0.17%	129
2023 Q1	$432K	Buy	5,218 +960	+23%	+$77.7K	0.11%	184
2022 Q4	$335K	Buy	4,258 +946	+29%	+$76K	0.1%	212
2022 Q3	$245K	Buy	+3,312	New	+$238K	0.09%	246

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vise Technologies's HAE Position: Q4 2024 in Review

Vise Technologies increased its Haemonetics (HAE) stake by 8.7% in Q4 2024, buying an estimated $18.1K and bringing the position to 2,825 shares worth $221K. The position accounts for 0.02% of the portfolio, ranked #728.

Vise Technologies first reported a position in HAE in Q3 2022 and has held it in 8 quarters since. The position peaked at $701K in Q2 2023. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

Vise Technologies held 2,825 shares of Haemonetics worth $221K as of Q4 2024.
Vise Technologies bought 225 Haemonetics shares in Q4 2024, an estimated $18.1K.
Haemonetics made up 0.02% of Vise Technologies's portfolio in Q4 2024, its #728 holding.
Vise Technologies first reported a position in Haemonetics in Q3 2022 and has held it in 8 quarters since.
Vise Technologies's Haemonetics position peaked at $701K in Q2 2023.
309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on Vise Technologies's 13F filing for Q4 2024, filed 18 Feb 2025.